Smith Anglin Financial’s ARK Genomic Revolution ETF ARKG Stock Holding History

Smith Anglin Financial’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16,366	Closed	-$1M	–	140
2021 Q4	$1M	Sell	16,366 -1,439	-8%	-$99.5K	0.17%	56
2021 Q3	$1.33M	Sell	17,805 -2,444	-12%	-$205K	0.26%	50
2021 Q2	$1.87M	Sell	20,249 -337	-2%	-$28.7K	0.36%	40
2021 Q1	$1.83M	Buy	20,586 +3,213	+18%	+$319K	0.39%	40
2020 Q4	$1.62M	Buy	+17,373	New	+$1.38M	0.29%	42

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Smith Anglin Financial's ARKG Position: Q1 2022 in Review

Smith Anglin Financial sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 16,366 shares — an estimated $1M sold.

Smith Anglin Financial first reported a position in ARKG in Q4 2020 and held it in 5 quarters. The position peaked at $1.87M in Q2 2021. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

Smith Anglin Financial reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
Smith Anglin Financial sold 16,366 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $1M.
Smith Anglin Financial first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 5 quarters.
Smith Anglin Financial's ARK Genomic Revolution ETF position peaked at $1.87M in Q2 2021.
387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Smith Anglin Financial's 13F filing for Q1 2022, filed 16 May 2022.